¾Ï ÁöÁö¿ä¹ý ¾àÁ¦ ½ÃÀå : Ä¡·á±ºº°, ¿ëµµº° - ¼¼°è Àü¸Á(2025-2030³â)
Cancer Supportive Care Drugs Market by Therapeutic Class (Antiemetics, Bisphosphonates, Erythropoiesis Stimulating Agents), Application (Breast Cancer, Colorectal Cancer, Liver Cancer) - Global Forecast 2025-2030
»óǰÄÚµå : 1586056
¸®¼­Ä¡»ç : 360iResearch Private Limited
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 190 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,939 £Ü 5,699,000
PDF, Excel & 1 Year Online Access (Single User License) help
PDF ¹× Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 4,249 £Ü 6,147,000
PDF, Excel & 1 Year Online Access (2-5 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿Àϱâ¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 5,759 £Ü 8,332,000
PDF, Excel & 1 Year Online Access (Site License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ Áö¿ª »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)
US $ 6,969 £Ü 10,083,000
PDF, Excel & 1 Year Online Access (Enterprise User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù. ¿Â¶óÀÎ Ç÷§Æû¿¡¼­ 1³â µ¿¾È º¸°í¼­¸¦ ¹«Á¦ÇÑÀ¸·Î ´Ù¿î·ÎµåÇÒ ¼ö ÀÖÀ¸¸ç, Á¤±âÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ´Â Á¤º¸µµ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. (¿¬ 3-4ȸ Á¤µµ ¾÷µ¥ÀÌÆ®)


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¾Ï ÁöÁö¿ä¹ý ¾àÁ¦ ½ÃÀåÀº 2023³â¿¡ 206¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 214¾ï 6,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 4.50%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿© 2030³â¿¡´Â 280¾ï 6,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¾Ï º¸Á¶¿ä¹ýÁ¦´Â ¾Ï Ä¡·á¿¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, Ä¡·á¿Í °ü·ÃµÈ ºÎÀÛ¿ëÀ» ¿ÏÈ­ÇÏ°í ¾Ï Ä¡·á Áß È¯ÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ ½ÃÀå¿¡´Â ±¸Åä ¾ïÁ¦Á¦, Á¶Ç÷ ¼ºÀå ÀÎÀÚ, ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ®, ÁøÅëÁ¦ µî ¾Ï Ä¡·á¿¡ ÈçÈ÷ µ¿¹ÝµÇ´Â ¸Þ½º²¨¿ò, ºóÇ÷, °ñÅë µîÀÇ Áõ»óÀ» °ü¸®Çϱâ À§ÇÑ ´Ù¾çÇÑ ¾àǰÀÌ Æ÷ÇԵ˴ϴÙ. Àü ¼¼°èÀûÀ¸·Î ¾Ï ¹ßº´·ü Áõ°¡¿Í È­Çпä¹ý ¹× ¹æ»ç¼± Ä¡·áÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ ÀÌ·¯ÇÑ º¸Á¶ ¾à¹°ÀÇ Çʿ伺ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°ÀÇ ¿ëµµ´Â ´Ù¾çÇÑ Á¾¾çÇÐ ºÐ¾ß¿¡ °ÉÃÄ ÀÖÀ¸¸ç, ÁÖ·Î º´¿ø, ¾Ï¼¾ÅÍ, ¿Ü·¡¿¡¼­ »ç¿ëµÇ¸ç, ¼ºÀΠȯÀÚ»Ó¸¸ ¾Æ´Ï¶ó ¼Ò¾Æ ȯÀÚµµ Áö¿øÇϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 206¾ï 2,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 214¾ï 6,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 280¾ï 6,000¸¸ ´Þ·¯
CAGR(%) 4.50%

ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â Á¾¾çÇÐ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ȯÀÚ Ä¡·á ¼öÁØ Çâ»ó¿¡ ´ëÇÑ °ü½É Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ ½ÃÀåÀº Ç¥ÀûÈ­µÈ ÁöÁö¿ä¹ý ¼Ö·ç¼Ç°ú Áõ»ó ¹× ¾à¹° ¼øÀÀµµ¸¦ º¸´Ù È¿°úÀûÀ¸·Î °ü¸®Çϱâ À§ÇÑ µðÁöÅÐ °Ç°­ µµ±¸ÀÇ ÅëÇÕ°ú °°Àº Çõ½ÅÀ¸·Î ÀÎÇØ ÀáÀçÀûÀÎ ºñÁî´Ï½º ±âȸ¸¦ ¸ñ°ÝÇϰí ÀÖ½À´Ï´Ù. ±Þ¼ÓÇÑ ±â¼ú ¹ßÀü°ú Á¦¾àȸ»ç¿Í ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü °£ÀÇ Çù·ÂÀû Á¢±ÙÀº ¾Ï Ä¡·áÀÇ ÁøÈ­ÇÏ´Â ¿ä±¸¸¦ Ȱ¿ëÇÒ ¼ö ÀÖ´Â Àü·«Àû ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¹Ý¸é, ³ôÀº Ä¡·áºñ, ±ÔÁ¦ À庮, Ä¡·á È¿°úÀÇ ÆíÂ÷°¡ ½ÃÀå È®´ëÀÇ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ä¡¿­ÇÑ °æÀï ȯ°æÀº »õ·Î¿î ȯÀÚ ´ÏÁî¿Í ±ÔÁ¦ ±âÁØÀ» ÃæÁ·Çϱâ À§ÇÑ ²÷ÀÓ¾ø´Â ±â¼ú Çõ½ÅÀ» ¿ä±¸Çϰí ÀÖ½À´Ï´Ù.

±â¼ú Çõ½Å°ú ¿¬±¸°¡ ÇÊ¿äÇÑ ºÐ¾ß¿¡´Â »õ·Î¿î ¾à¹° Àü´Þ ¸ÞÄ¿´ÏÁò °³¹ß, ºñ¿ë Àý°¨À» À§ÇÑ ¹ÙÀÌ¿À½Ã¹Ð·¯ Ž»ö, º¸¿Ï´ëü¿ä¹ý ¿¬±¸ µîÀÌ ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ Æ¯¼ºÀº ¿ªµ¿ÀûÀÌ°í »õ·Î¿î °úÇÐÀû ±Ù°Å¿Í ±â¼ú¿¡ Å©°Ô ÀÇÁ¸Çϰí Àֱ⠶§¹®¿¡ Á¾ÇÕÀûÀÎ ½ÃÀå Àü·«°ú ÀÇ·á ½Ã½ºÅÛ°úÀÇ Çù·ÂÀÇ Çʿ伺ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î, ¾Ï º¸Á¶¿ä¹ý ºÐ¾ß¿¡¼­ Àå±âÀûÀÎ ¼ºÀå°ú ¿µÇâ·ÂÀ» È®º¸ÇϰíÀÚ ÇÏ´Â ÀÌÇØ°ü°èÀڵ鿡°Ô´Â È¿°ú¿Í ¾ÈÀü¼º Çâ»ó¿¡ ÁßÁ¡À» µÎ¸é¼­ Á¢±Ù¼º°ú ºñ¿ë È¿À²¼º¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ôÀÌ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ¾Ï Áö¿ø Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® ÆÄ¾ÇÇϱâ

¾Ï º¸Á¶¿ä¹ý ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Portre's Five Forces: ¾Ï Áö¿ø Ä¡·áÁ¦ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·«Àû µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¾Ï º¸Á¶Ä¡·áÁ¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¾Ï Áö¿ø Ä¡·áÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ¾ÏÁöÁö¿ä¹ýÁ¦ ½ÃÀå °æÀï»óȲ ÆÄ¾Ç

¾Ï Áö¿ø Ä¡·áÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ¾ÏÁöÁö¿ä¹ýÁ¦ ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¾Ï Áö¿ø Ä¡·áÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÒ ¼ö ÀÖ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ ¾Ï º¸Á¶¿ä¹ýÁ¦ ½ÃÀå¿¡¼­ ¼º°øÀÇ ±æÀ» ±×¸®´Ù.

¾Ï Áö¿ø Ä¡·áÁ¦ ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

Á¦6Àå ¾Ï ÁöÁö¿ä¹ý ¾àÁ¦ ½ÃÀå : Ä¡·á Ŭ·¡½ºº°

Á¦7Àå ¾Ï ÁöÁö¿ä¹ý ¾àÁ¦ ½ÃÀå : ¿ëµµº°

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ ¾Ï ÁöÁö¿ä¹ý ¾àÁ¦ ½ÃÀå

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾Ï ÁöÁö¿ä¹ý ¾àÁ¦ ½ÃÀå

Á¦10Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¾Ï ÁöÁö¿ä¹ý ¾àÁ¦ ½ÃÀå

Á¦11Àå °æÀï ±¸µµ

±â¾÷ ¸®½ºÆ®

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Cancer Supportive Care Drugs Market was valued at USD 20.62 billion in 2023, expected to reach USD 21.46 billion in 2024, and is projected to grow at a CAGR of 4.50%, to USD 28.06 billion by 2030.

Cancer supportive care drugs are crucial in oncology, providing relief from treatment-related side effects and enhancing patients' quality of life during cancer therapies. This market encompasses a wide range of medications, including antiemetics, hematopoietic growth factors, bisphosphonates, and analgesics, aimed at managing symptoms like nausea, anemia, and bone pain commonly associated with cancer treatments. The growing prevalence of cancer worldwide and advancements in chemotherapy and radiation therapies underscore the necessity for these supportive drugs. The application of these drugs spans across various oncology departments and is primarily utilized by hospitals, cancer centers, and outpatient facilities, where they support not only adult patients but pediatric cases as well.

KEY MARKET STATISTICS
Base Year [2023] USD 20.62 billion
Estimated Year [2024] USD 21.46 billion
Forecast Year [2030] USD 28.06 billion
CAGR (%) 4.50%

Key growth influencers include the increasing investment in oncology research, the rising demand for personalized medicine, and the focus on improving patient care standards. Additionally, the market is witnessing potential opportunities driven by innovations such as targeted supportive care solutions and the integration of digital health tools to manage symptoms and medication adherence more effectively. Rapid technological advancements and a collaborative approach between pharmaceutical companies and healthcare providers offer strategic opportunities to capitalize on the evolving needs of cancer care. Meanwhile, limitations such as high treatment costs, regulatory hurdles, and the variable efficacy of supportive drugs pose challenges to market expansion. Moreover, the competitive landscape can be stringent, requiring constant innovation to meet emerging patient needs and regulatory standards.

Areas ripe for innovation and research include the development of novel drug delivery mechanisms, exploration of biosimilars to reduce costs, and investigation into complementary and alternative therapies. The nature of the market is dynamic and heavily reliant on emerging scientific evidence and technology, emphasizing the need for comprehensive market strategies and collaboration with healthcare systems. Overall, maintaining a focus on enhancing efficacy and safety, while addressing accessibility and cost-effectiveness, will be crucial for stakeholders aiming to achieve long-term growth and impact in the cancer supportive care sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Supportive Care Drugs Market

The Cancer Supportive Care Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Supportive Care Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Supportive Care Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Supportive Care Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Supportive Care Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Supportive Care Drugs Market

A detailed market share analysis in the Cancer Supportive Care Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Supportive Care Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Supportive Care Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Supportive Care Drugs Market

A strategic analysis of the Cancer Supportive Care Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Supportive Care Drugs Market, highlighting leading vendors and their innovative profiles. These include Acacia Pharma Group PLC, Amgen Inc., Aphios Corporation, AstraZeneca PLC, Bayer AG, Celldex Therapeutics, GSK PLC, Helsinn Healthcare SA, Heron Pharma, Ipsen Pharma, Johnson & Johnson, Merck & Co., Novartis International AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Supportive Care Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

6. Cancer Supportive Care Drugs Market, by Therapeutic Class

7. Cancer Supportive Care Drugs Market, by Application

8. Americas Cancer Supportive Care Drugs Market

9. Asia-Pacific Cancer Supportive Care Drugs Market

10. Europe, Middle East & Africa Cancer Supportive Care Drugs Market

11. Competitive Landscape

Companies Mentioned

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â